Article
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.
Leukemia - 1 Jul 2017
Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton L-A, Blakemore S J, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt C A, Smedby K E, Juliusson G, Giacopelli B, Blachly J S, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak A W, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard O A, Nguyen-Khac F, Rassenti L, Li J, Kipps T J, Stamatopoulos K, Pospisilova S, Zenz T, Oakes C C, Strefford J C, Rosenquist R, Damm F
Abstract excerpt
Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.